Trevi Therapeutics (TRVI) announced that David Hastings will assume the role of CFO effective January 6, 2026. Most recently, Hastings was CFO at Arbutus from June 2018 until March 2025. Previously, he was CFO of Unilife from 2015 until 2017. Prior to that, he spent the majority of his career as CFO and Executive Vice President at Incyte, a role he held from 2003 to 2014. Hastings also previously served as Vice President, CFO and Treasurer at ArQule.Currently, Hastings is a Board member and Chair of the Audit Committee of Scynexis.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Positive Developments and Strategic Advancements Boost Trevi Therapeutics’ Buy Rating
- Trevi Therapeutics price target raised to $16 from $13 at Leerink
- Trevi Therapeutics’ Earnings Call Highlights Promising Outlook
- Trevi Therapeutics price target raised to $19 from $18 at Morgan Stanley
- Trevi Therapeutics price target raised to $24 from $23 at Oppenheimer